The FDA wants to know what’s the ideal context for risk info. Some experts assert that the question misses the point.
Whether Apple’s foray into med devices will change the screening landscape for the better isn’t entirely clear, clinicians say.
Some of the world’s most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald Trump.
The holding company has launched a review of its Publicis Health Solutions business after a volatile Q2.
Wednesday’s reorg was designed to position the company for growth in the face of the imminent patent cliff for megablockbuster Lyrica.